目的:COVID-19大流行表明,心血管疾病的死亡风险更高。对这些患者的脂质治疗提出了疑问。目的是分析降脂治疗对COVID-19患者的疗效和安全性。
方法:在PubMed,CDC报告,NIH,和NCBISARS-CoV-2使用关键词:COVID-2,他汀类药物,ezetimibe,PCSK9抑制剂,高胆固醇血症,和降血脂药物.
结果:他汀类药物应根据其疗效继续使用COVID-19患者,安全,免疫抑制作用,抗炎的可用性和可及性。根据这些患者的心血管风险水平,高和极高心血管风险患者可能需要使用高效他汀类药物和/或依泽替米贝和/或iPCSK9.使用iPCSK9治疗的患者应继续治疗其预防心血管疾病的有益作用。家族性高胆固醇血症和COVID-19患者特别容易患心血管疾病,应继续接受严重的降脂治疗。
结论:在COVID-19患者中,大多数基线CVD是动脉粥样硬化起源,对CVD高风险和极高风险患者的预测最差。在这些患者中,他汀类药物的强化治疗和/或依泽替米贝和/或iPCSK9的固定联合治疗起着重要作用。
OBJECTIVE: The COVID-19 pandemic has shown that cardiovascular diseases carry a higher risk of mortality. Doubts have been raised regarding lipid therapy in these patients. The objectives are to analyze the efficacy and safety of lipid lowering therapy in patients with COVID-19.
METHODS: A review of the scientific literature was conducted in PubMed, CDC Reports, NIH, and NCBI SARS-CoV-2 using the keywords: COVID-2, statins, ezetimibe, PCSK9 inhibitors, hypercholesterolemia, and hypolipidemic drugs.
RESULTS: The statins should continue to use patients with COVID-19 based on their efficacy, safety, immunosuppressive effects, anti-inflammatory availability and accessibility. Depending on the cardiovascular risk levels of these patients, the use of high potency statins and/or ezetimibe and/or iPCSK9 may be necessary in patients with high and very high cardiovascular risk. Patients treated with iPCSK9 should continue treatment for its beneficial effects in preventing cardiovascular disease. Patients with familial hypercholesterolemia and COVID-19 are especially vulnerable to cardiovascular disease and should continue to receive severe lipid lowering therapy.
CONCLUSIONS: In patients with COVID-19, the majority of baseline CVDs are of atherosclerotic origin, with the worst prediction for patients with high risk and very high risk of CVD. In these patients, intensive treatment with statins and/or fixed combination with ezetimibe and/or iPCSK9 plays a fundamental role.